NYSEAMERICAN:AIM

AIM ImmunoTech (AIM) Stock Price, News & Analysis

AIM ImmunoTech logo
$0.13 -0.01 (-8.77%)
Closing price 04:10 PM Eastern
Extended Trading
$0.13 +0.00 (+2.29%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About AIM ImmunoTech Stock (NYSEAMERICAN:AIM)

Advanced

Key Stats

Today's Range
$0.13
▼
$0.15
50-Day Range
$0.13
▼
$0.23
52-Week Range
$0.12
▼
$1.88
Volume
645,253 shs
Average Volume
10.55 million shs
Market Capitalization
$3.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Moderate Buy

Company Overview

AIM ImmunoTech is a biotechnology company focused on developing treatments that activate or modulate the immune system. Its work centers on Ampligen (rintatolimod), an investigational drug designed to stimulate immune responses and studied in clinical research for conditions including myalgic encephalomyelitis/chronic fatigue syndrome and certain cancers.

The company also has rights to Alferon N, a natural interferon product approved in the United States for a specific use in patients with recurrent or refractory external genital warts. AIM’s activities include research and development, clinical testing, and potential commercialization of its products.

Previously known as Hemispherx Biopharma, the company adopted the AIM ImmunoTech name in 2019. Its development and regulatory activities have principally been conducted in the United States, with research programs also involving international collaborators.

AI Generated. May Contain Errors.

AIM ImmunoTech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

AIM MarketRank™: 
3.198198198195 of 5 stars

AIM ImmunoTech scored higher than 64% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AIM ImmunoTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

  • Upside Potential

    AIM ImmunoTech has a consensus price target of $9.00, representing about 6,770.2% upside from its current price of $0.13.

  • Amount of Analyst Coverage

    AIM ImmunoTech has received no research coverage in the past 90 days.

  • Read more about AIM ImmunoTech's stock forecast and price target.
  • Earnings Growth

    Earnings for AIM ImmunoTech are expected to grow in the coming year, from ($0.78) to ($0.37) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AIM ImmunoTech is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AIM ImmunoTech is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    3.32% of the float of AIM ImmunoTech has been sold short.
  • Short Interest Ratio / Days to Cover

    AIM ImmunoTech has a short interest ratio ("days to cover") of 2.46, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AIM ImmunoTech has recently decreased by 7.21%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    AIM ImmunoTech does not currently pay a dividend.

  • Dividend Growth

    AIM ImmunoTech does not have a long track record of dividend growth.

  • News Sentiment

    AIM ImmunoTech has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for AIM ImmunoTech this week, compared to 3 articles on an average week.
  • Search Interest

    Only 8 people have searched for AIM on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added AIM ImmunoTech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $42,522.00 in company stock, which represents 1.0663% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, AIM ImmunoTech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $42,522.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    0.82% of the stock of AIM ImmunoTech is held by insiders.

  • Percentage Held by Institutions

    12.02% of the stock of AIM ImmunoTech is held by institutions.

  • Read more about AIM ImmunoTech's insider trading history.
Receive AIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AIM Stock News Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Headlines

AIM Stock Analysis - Frequently Asked Questions

AIM ImmunoTech's stock was trading at $1.1289 at the start of the year. Since then, AIM stock has decreased by 88.4% and is now trading at $0.1310.

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) released its quarterly earnings data on Thursday, November, 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.12. The business had revenue of $22 thousand for the quarter. AIM ImmunoTech had a negative trailing twelve-month return on equity of 789.11% and a negative net margin of 15,526.38%.

AIM ImmunoTech shares reverse split on the morning of Thursday, June 12th 2025.The 1-100 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Tesla (TSLA), NIO (NIO), Nokia (NOK), Vaxart (VXRT), FuelCell Energy (FCEL), iBio (IBIO) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
11/12/2026
Today
11/16/2026
AGM 2026
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NYSEAMERICAN:AIM
Previous Symbol
NYSEAMERICAN:HEB
CIK
946644
Employees
21
Year Founded
1990

Price Target and Rating

High Price Target
$9.00
Low Price Target
$9.00
Potential Upside/Downside
+6,770.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($24.68)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.96 million
Net Margins
-15,526.38%
Pretax Margin
-15,526.38%
Return on Equity
-789.11%
Return on Assets
-153.37%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.75
Quick Ratio
2.75

Sales & Book Value

Annual Sales
$90 thousand
Price / Sales
44.31
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.99) per share
Price / Book
-0.04

Miscellaneous

Outstanding Shares
30,440,000
Free Float
30,192,000
Market Cap
$3.99 million
Optionable
Not Optionable
Beta
1.32

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NYSEAMERICAN:AIM) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners